on Marinomed Biotech AG
Marinomed Biotech AG Reports Positive Trial Results for Tacrolimus Eye Drops
Marinomed Biotech AG has published promising results from a phase II clinical trial on Tacrosolv eye drops. The study, featured in the "Clinical Ophthalmology" journal, demonstrates the drops' effectiveness in alleviating symptoms of allergic rhinoconjunctivitis. Tacrosolv, a low-dose aqueous formulation of Tacrolimus, is found to be both safe and efficient.
The placebo-controlled trial tested two different doses, showing significant reductions in ocular symptoms with a higher dose (0.005% Tacrolimus). Notably, nasal symptoms linked to allergies were also alleviated. This is significant as Tacrosolv uses a dose 20 times lower than existing market products.
The study involved adults with allergic conjunctivitis, revealing reduced symptoms within just 8 days. Marinomed's Marinosolv technology enhances Tacrolimus solubility, improving bioavailability and speeding up symptom relief. The findings suggest Tacrosolv as a viable treatment for inflammatory eye conditions.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Marinomed Biotech AG news